LDL-C reduction and saphenous vein graft patency after CABG surgery

Q: What is the clinical evidence from this study?

Study design: Editorial. Population: Coronary artery bypass grafting surgery (CABG) (n=499). Intervention: Decrease in LDL-C (per 1 mmol/L) from baseline to three months. Primary outcome: Saphenous vein graft disease (OR 0.74, 95% CI 0.64-0.98).

Q: What does this research mean for the field?

Each 1 mmol/L decrease in LDL-C achieved at three months following CABG is associated with a 26% relative reduction in the risk of saphenous vein graft disease at two years. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Tobin Joseph; Ramesh Nadarajah; Chris Gale

doi:10.1093/eurjpc/zwag324

June 11, 2026European Journal of Preventive CardiologyOpen Access

LDL-C reduction and saphenous vein graft patency after CABG surgery

View Full Paper

Ask AI

Bookmark

Share

Key result

For every 1 mmol/L decrease in LDL-C from baseline to three months, there was a 26% relative reduction in the risk of saphenous vein graft disease.

Why the study?

Does greater early LDL-C reduction improve saphenous vein graft patency at two years in patients undergoing CABG surgery?

Key Points

To evaluate whether achieving lower levels of low-density lipoprotein cholesterol (LDL-C) after coronary artery bypass grafting (CABG) surgery is associated with improved saphenous vein graft patency and reduced occlusion.
Post-hoc analysis of the international, multicenter randomized NEWTON-CABG CardioLink-5 trial evaluating 499 participants with 1198 saphenous vein grafts receiving evolocumab or placebo alongside statin therapy.
Assessed the association between achieved LDL-C and non-HDL-C levels at 3 months postoperatively and graft patency or plaque volume at 24 months using computed tomography angiography or invasive angiography.
Every 1 mmol/L reduction in LDL-C from baseline to 3 months was associated with a 26% lower risk of saphenous vein graft disease at 2 years (OR 0.74, 95% CI 0.64–0.98).
Each 1 mmol/L decrease in LDL-C was similarly associated with reduced total graft occlusion (OR 0.76, 95% CI 0.60–0.96).
Participants receiving evolocumab experienced lower rates of graft stenosis compared with the control arm (mean 0.46 vs 0.51 per participant).

Structured PICO

Does greater early LDL-C reduction improve saphenous vein graft patency at two years in patients undergoing CABG surgery?

P

Population

499 participants with 1198 saphenous vein grafts who underwent CABG, comprising 14% females and 45% with prior myocardial infarction, evaluated at 2 years postoperatively.

E

Exposure

Greater LDL-C reduction (from baseline to three months post-operatively), analyzed regardless of randomized treatment assignment (evolocumab vs placebo).

C

Comparator

Lesser LDL-C reduction from baseline to three months.

O

Outcome

Saphenous vein graft patency and plaque volume (proportion of saphenous vein grafts with ≥50% occlusion or total occlusion) measured using coronary computed coronary angiography or clinically indicated invasive angiography at 24 months.surrogate

Main Result

Odds Ratio: 0.74 (95% CI 0.64–0.98)

Limitations

Relatively short follow-up duration limits insight into mechanisms of graft failure
Single assessment of graft status at two years may not capture the timing or dominant pathological processes
Observations should be interpreted as associations rather than causal
Post-hoc analysis showing associations rather than causality
Relatively short follow-up duration of 24 months
Single assessment of graft status at two years may not capture timing or dominant pathological processes of graft deterioration

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Greater magnitude of early LDL-C reduction after CABG is associated with improved saphenous vein graft patency at two years, highlighting the value of early post-operative lipid optimization.

Abstract

Tobin Joseph, Ramesh Nadarajah, Chris P Gale; LDL-C reduction and saphenous vein graft patency after CABG surgery, European Journal of Preventive Cardiolog

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Joseph et al. (2026) conducted an editorial in Coronary artery bypass grafting surgery (CABG) (n=499). Decrease in LDL-C (per 1 mmol/L) from baseline to three months was evaluated on Saphenous vein graft disease (OR 0.74, 95% CI 0.64-0.98). For every 1 mmol/L decrease in LDL-C from baseline to three months, there was a 26% relative reduction in the risk of saphenous vein graft disease.

synapsesocial.com/papers/6a33cfcf14a9c556e667788c https://doi.org/10.1093/eurjpc/zwag324

View Full Paper

Ask AI

Bookmark

Share

LDL-C reduction and saphenous vein graft patency after CABG surgery

Key Points

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

LDL-C reduction and saphenous vein graft patency after CABG surgery

Key Points

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading